Cost effectiveness of polatuzumab vedotin in combination with chemoimmunotherapy (Pola-R-CHP) in previously untreated diffuse large B-cell lymphoma.

被引：0
|
作者：
Kambhampati, Swetha
Saumoy, Monica
Pak, Stacy
Budde, L. Elizabeth
Mei, Matthew Genyeh
Popplewell, Leslie
Wen, Yi-Ping
Forman, Stephen J.
Kwak, Larry W.
Rosen, Steven T.
Herrera, Alex Francisco
Thiruvengadam, Nikhil
机构：
[1] City Hope Natl Med Ctr, Duarte, CA USA
[2] Penn Med Princeton Med Ctr, Plainsboro, NJ USA
[3] City Hope Natl Med Ctr, Duarte, CA USA
[4] City Hope Comprehens Canc Ctr, Duarte, CA USA
[5] Univ Texas MD Anderson Canc Ctr Chairman, Houston, TX USA
[6] Loma Linda Univ, Loma Linda, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7568
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Cost-effectiveness of polatuzumab vedotin in combination with chemoimmunotherapy (pola-R-CHP) in previously untreated diffuse large B-cell lymphoma in Germany
    Kambhampati, Swetha
    Shumilov, Evgenii
    Saumoy, Monica
    Herrera, Alex F.
    Tilly, Herve
    Lenz, Georg
    Thiruvengadam, Nikhil R.
    BRITISH JOURNAL OF HAEMATOLOGY, 2023, 202 (04) : 771 - 775
  • [2] POLA-R-CHP: POLATUZUMAB VEDOTIN COMBINED WITH RITUXIMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN, PREDNISONE FOR PATIENTS WITH PREVIOUSLY UNTREATED DIFFUSE LARGE B-CELL LYMPHOMA
    Tilly, H.
    Sharman, J.
    Bartlett, N.
    Morschhauser, F.
    Haioun, C.
    Munoz, J.
    Chen, A.
    Lamy, T.
    Wang, L.
    Penuel, E.
    Hirata, J.
    Lee, C.
    Salles, G.
    HAEMATOLOGICA, 2017, 102 : 4 - 4
  • [3] Cost-Effectiveness of Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma
    Matasar, Matthew
    Masaquel, Anthony
    Rodrigo, Ho
    Launonen, Aino
    Ng, Carmen
    Wang, Rongrong
    Fox, David
    Hossain, Farah
    Li, Jia
    Roth, Joshua A.
    Burke, John M.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S359 - S360
  • [4] Cost-effectiveness of polatuzumab vedotin combined with chemoimmunotherapy in untreated diffuse large B-cell lymphoma
    Kambhampati, Swetha
    Saumoy, Monica
    Schneider, Yecheskel
    Pak, Stacy
    Budde, Lihua Elizabeth
    Mei, Matthew G.
    Siddiqi, Tanya
    Popplewell, Leslie L.
    Wen, Yi-Ping
    Zain, Jasmine
    Forman, Stephen J.
    Kwak, Larry W.
    Rosen, Steven T.
    Danilov, Alexey V.
    Herrera, Alex F.
    Thiruvengadam, Nikhil R.
    BLOOD, 2022, 140 (25) : 2697 - 2708
  • [5] Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma
    Tilly, Herve
    Morschhauser, Franck
    Sehn, Laurie H.
    Friedberg, Jonathan W.
    Trneny, M.
    Sharman, Jeff P.
    Herbaux, Charles
    Burke, John M.
    Matasar, Matthew
    Rai, Shinya
    Izutsu, Koji
    Mehta-Shah, Neha
    Oberic, Lucie
    Chauchet, Adrien
    Jurczak, Wojciech
    Song, Yuqin
    Greil, Richard
    Mykhalska, Larysa
    Bergua-Burgues, Juan M.
    Cheung, Matthew C.
    Pinto, Antonio
    Shin, Ho-Jin
    Hapgood, Greg
    Munhoz, Eduardo
    Abrisqueta, Pau
    Gau, Jyh-Pyng
    Hirata, Jamie
    Jiang, Yanwen
    Yan, Mark
    Lee, Calvin
    Flowers, Christopher R.
    Salles, Gilles
    NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (04): : 351 - 363
  • [6] US cost-effectiveness analysis of polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma
    Matasar, Matthew
    Masaquel, Anthony
    S. Ho, Rodrigo
    Launonen, Aino
    Ng, Carmen D.
    Wang, Rongrong
    Fox, David
    Hossain, Farah
    Li, Jia
    Burke, John M.
    JOURNAL OF MEDICAL ECONOMICS, 2023, 26 (01) : 1134 - 1144
  • [7] COST-EFFECTIVENESS ANALYSIS OF POLATUZUMAB VEDOTIN COMBINED WITH CHEMOIMMUNOTHERAPY IN UNTREATED DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) IN CHINA
    Bai, X.
    Shao, R.
    Zhen, B.
    Xia, Y.
    He, X.
    VALUE IN HEALTH, 2023, 26 (12) : S189 - S189
  • [8] Polatuzumab-R-CHP in Previously Untreated Diffuse Large B-Cell Lymphoma: A Retrospective Study
    Bobes, Alejandro
    Llorente, Laura
    Pradillo, Virginia
    Alonso, Aranzazu
    Fernandez, Ruben
    Garcia-Noblejas, Ana
    Lopez de la Osa, M. Jose
    Casanova, Maria
    Lorente, Soraya
    Iglesias, Rebeca
    Estevez, Monica
    De Ona, Raquel
    De La Fuente, Adolfo
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S479 - S479
  • [9] Is first-line treatment with polatuzumab vedotin-rituximab-cyclophosphamide, doxorubicin and prednisone (pola-R-CHP) for previously untreated diffuse large B-cell lymphoma cost-effective in China? A cost-effectiveness analysis using a Markov model
    Dong, Liangliang
    Zhong, Wanfu
    Chen, Ting
    Zhao, Qiuling
    Liu, Wenbin
    Qiu, Xiuliang
    Huang, Ruyi
    Huang, Shengqiang
    Xie, Ruixiang
    Yang, Lin
    BMJ OPEN, 2025, 15 (01):
  • [10] The POLARIX Study: Polatuzumab Vedotin with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) Therapy in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma
    Tilly, Herve
    Morschhauser, Franck
    Sehn, Laurie H.
    Friedberg, Jonathan W.
    Trneny, Marek
    Sharman, Jeff P.
    Herbaux, Charles
    Burke, John M.
    Matasar, Matthew
    Rai, Shinya
    Izutsu, Koji
    Mehta-Shah, Neha
    Oberic, Lucie
    Chauchet, Adrien
    Jurczak, Wojciech
    Song, Yuqin
    Greil, Richard
    Mykhalska, Larysa
    Bergua Burgues, Juan Miguel
    Cheung, Matthew C.
    Pinto, Antonio
    Shin, Ho-Jin
    Hapgood, Greg
    Munhoz, Eduardo
    Abrisqueta Costa, Pau
    Gau, Jyh-Pyng
    Hirata, Jamie
    Jiang, Yanwen
    Yan, Mark
    Lee, Calvin
    Flowers, Christopher R.
    Salles, Gilles
    BLOOD, 2021, 138
12345